CClinicalTrials.gg
CompletedNCT03402126TPDUpdated Nov 16, 2021Results posted

Tachy Prediction Download Study

An observational study in Ventricular Tachycardia, sponsored by Medtronic Cardiac Rhythm and Heart Failure. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-16.

Sponsored by Medtronic Cardiac Rhythm and Heart Failure · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
138
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the Medtronic Tachy Prediction Download (TPD) study is to collect data from an implantable cardiac defibrillator (ICD) device that will be used to identify markers for imminent onset of ventricular arrhythmias.

Read the detailed description

The TPD Study is a prospective, non-randomized, non-interventional, multi-site data collection clinical study to collect ICD longitudinal data that may be used to develop a VT/VF prediction algorithm. The study subjects will include patients currently implanted, or who will be implanted with a market-approved Medtronic Evera MRI® ICD.

02

Conditions studied

  • Ventricular Tachycardia
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study subjects will include patients currently implanted, or who will be implanted with a market-approved Medtronic Evera MRI® ICD.

Inclusion criteria

  • Subject is implanted or will be implanted, with an Evera MRI device with properly functioning Medtronic tachycardia lead placed in the right ventricle (with or without atrial lead) with remaining device longevity of 4 years or more for:

    • Secondary Prevention or,
    • Primary Prevention and has had a device treated VT/VF or a device recorded episode of sustained VT/VF
  • Subject is ≥ 18 years old
  • Subject has previously documented history of VT/VF
  • Subject must be willing and able to use Medtronic CareLink network monitoring system
  • Subject provides signed and dated authorization and/or consent per institution and local requirements
  • Subject is willing and able to comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • Subject who received device for Primary Prevention indication and who has not had either a device treated VT/VF episode or a device recorded episode of sustained VT/VF
  • Subject is enrolled in a concurrent study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
  • Subject has chronic AF
  • Subject has inherited disorders of ion transport mechanisms that predispose the subject to sudden death ("Channelopathies"): Long QT and Brugada Syndromes
  • Subject with multiple implanted active devices that may cause an interruption of a transmission of device data to CareLink
  • Subject has active electronic medical device other than an ICD
  • Subject requires more than 25% atrial or ventricular pacing
  • Subject has medical conditions that would limit study participation (per investigator judgment)
  • Subject has projected life expectancy of less than 1 year
  • Subject is pregnant or plans to be pregnant over the next year (females of child-bearing potential must have a negative pregnancy test within one week of enrollment and must practice a reliable form of birth control while enrolled in the study)
  • Subject meets exclusion criteria required by local law (e.g. age, breastfeeding, etc.)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
138 participants (actual)
Patient registry
No

Groups and cohorts

  • TPD RAMWare Download

    Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.

    Other: TPD RAMWare

Interventions

  • OtherTPD RAMWare

    TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use

05

What researchers measure

Primary outcomes

  1. Number of Participants With Device Detected Ventricular Tachycardia/Ventricular Fibrillation Episodes

    This was a data collection study collecting data when implanted device detected Ventricular Tachycardia/Ventricular Fibrillation.

    Time frame: 1 year

06

Results

Posted Nov 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneTPD RAMWare Download
Started138
Completed76
Not completed62
Withdrew: Lost to follow-up6
Withdrew: Protocol violation10
Withdrew: Sponsor request/study termination29
Withdrew: Study product no longer in use1
Withdrew: Technical problems1
Withdrew: Withdrawal by subject6
Withdrew: Physician decision2
Withdrew: Upgrade to cardiac resynchronization therapy-defibrillator/stage iv cancer3
Withdrew: Death4

Outcome measures

PrimaryNumber of Participants With Device Detected Ventricular Tachycardia/Ventricular Fibrillation Episodes

This was a data collection study collecting data when implanted device detected Ventricular Tachycardia/Ventricular Fibrillation.

Time frame:
1 year
Reported as:
Count of participants · Participants
Number of Participants With Device Detected Ventricular Tachycardia/Ventricular Fibrillation Episodes
ParticipantsTPD RAMWare Download
Participants with device detected ventricular tachycardia/ventricular fibrillation episodes31
Participants with no device detected ventricular tachycardia/ventricular fibrillation episode97

Adverse events

Collected over 1 year (12 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TPD RAMWare Download4/128 (3.1%)0/128 (0%)0/128 (0%)

Baseline characteristics

Total number of all participants for whom baseline characteristics were measured and received the Ramware injection. 138 participants were assessed for eligibility but only 128 had baseline characteristics measured and received the Ramware injected. 10 participants did not receive Ramware injection and undergo baseline characteristic measurements due to 8 experiencing screen failures, 1 experiencing noncompliance, and 1 being removed due to physician decision.

Age, Continuous
Age, Continuous(years)TPD RAMWare Injected
Mean62 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)TPD RAMWare Injected
Female24
Male104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TPD RAMWare Injected
Hispanic or Latino1
Not Hispanic or Latino126
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TPD RAMWare Injected
American Indian or Alaska Native0
Asian29
Native Hawaiian or Other Pacific Islander0
Black or African American12
White81
More than one race0
Unknown or Not Reported6
Region of Enrollment
Region of Enrollment(participants)TPD RAMWare Injected
Hong Kong28
United States100
Body Mass Index
Body Mass Index(kg/m^2)TPD RAMWare Injected
Mean29.8 ± 6.9
Weight
Weight(kg)TPD RAMWare Injected
Mean90.1 ± 22.5
Height
Height(cm)TPD RAMWare Injected
Mean173.8 ± 10.0
07

Study locations

16 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Iowa Heart Center
    Des Moines, Iowa 50266, United States
  • Beaumont Hospital - Royal Oak
    Royal Oak, Michigan 48073, United States
  • CentraCare Heart & Vascular Center
    Saint Cloud, Minnesota 56303, United States
  • United Heart and Vascular Clinic
    Saint Paul, Minnesota 55102, United States
  • Saint Lukes Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Bryan Heart
    Lincoln, Nebraska 68506, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07960, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Cape Fear Heart Associates
    Wilmington, North Carolina 28401, United States
  • Mount Carmel East
    Columbus, Ohio 43213, United States
  • Oklahoma Heart Hospital Research Foundation
    Oklahoma City, Oklahoma 73120, United States
  • The Stern Cardiovascular Foundation
    Germantown, Tennessee 38138, United States
  • Centennial Heart Cardiovascular Consultants
    Nashville, Tennessee 37203, United States
  • Texas Cardiac Arrhythmia Research Foundation
    Austin, Texas 78705, United States
  • Princess Margaret Hospital
    Hong Kong, Hong Kong
08

References and documents

Study documents

  • Study protocol · Aug 1, 2017
  • Statistical analysis plan · Nov 21, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03402126
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Jan 12, 2018
Primary completion
Feb 26, 2020
Completion
Feb 26, 2020
Results posted
Nov 16, 2021
Last update
Nov 16, 2021

Study contacts

Mark Brown
study director · Medtronic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion